(3.230.143.40) 您好!臺灣時間:2021/04/21 06:03
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:王斯郁
論文名稱:Clodronate及Paclitaxel對人類肝癌細胞株之作用評估
論文名稱(外文):The effects of clodronate and paclitaxel on human hepatoma cell lines
指導教授:何禮剛何禮剛引用關係戚謹文
學位類別:碩士
校院名稱:國立陽明大學
系所名稱:藥理學研究所
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2003
畢業學年度:91
語文別:中文
論文頁數:125
中文關鍵詞:ClodronatePaclitaxel肝癌雙磷酸鹽鈣離子紫杉醇HepG2HA22T/VGH
相關次數:
  • 被引用被引用:2
  • 點閱點閱:220
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:32
  • 收藏至我的研究室書目清單書目收藏:0
雙磷酸鹽藥物為人體內生性焦磷酸鹽的類似物,具有抑制骨耗損的能力,臨床上對於Paget’s disease、惡性疾病引起之高血鈣及癌症所產生的骨轉移等現象都具有明顯的治療效果。除了對於噬骨細胞的作用之外,曾有實驗證實雙磷酸鹽藥物也具有誘導某些癌細胞進行凋亡之能力;在進行骨骼掃描時發現這類藥物會大量蓄積在肝癌組織中,顯示雙磷酸鹽藥物對於肝癌具有高度親和力,因此本實驗使用第二代雙磷酸鹽藥物clodronate觀察其對於肝癌細胞株HepG2及HA22T/VGH生長的抑制情形,並與另一種抗癌藥物paclitaxel合併使用,觀察這兩種藥物之間是否具有加成或協同之作用。在不同濃度clodronate或paclitaxel處理後,細胞的生長及存活率都會隨著藥物濃度及處理時間的增加而明顯受到抑制。以流式細胞儀分析細胞週期變化時,發現以clodronate處理後細胞週期會呈現G0/G1波峰比例增加及S期減少的現象;而paclitaxel則會將大部分細胞停滯在G2/M期。進一步探討藥物對於細胞內鈣離子濃度的影響,以clodronate處理後會使細胞內鈣離子濃度隨著藥物的劑量呈現不同的變化,若改以局部給藥的刺激方式觀察細胞內鈣離子濃度的即時反應時,發現clodronate刺激會造成HepG2細胞的鈣離子濃度暫時下降,但並不影響HA22T/VGH細胞內的鈣離子濃度。若以paclitaxel局部刺激則會使HepG2細胞的鈣離子濃度增加,使用thapsigargin處理後發現paclitaxel引起之鈣離子濃度增加的現象可能是透過刺激細胞內質網中儲存的鈣離子釋放出來所導致。Clodronate及paclitaxel同時給予時,會使HA22T/VGH細胞對於paclitaxel產生多倍體的比例較單獨使用paclitaxel時降低,但兩種藥物併用後對於細胞生長的抑制作用與paclitaxel單獨使用時相比並無明顯增加的情形。若以clodronate先對細胞進行預處理再加入paclitaxel的給藥方式,則會使細胞週期中G0/G1波峰的比例較單獨使用paclitaxel時略為增加,且會明顯降低paclitaxel所引起的週期蛋白E增加的現象。綜合來說,clodronate具有抑制肝癌細胞生長的能力,而當它與paclitaxel併用時雖然可觀察到些微的差異,但並不能增加paclitaxel對於細胞生長之抑制作用。
中文摘要…………………………………………………………....1
英文摘要……………………………………………………………2
縮寫表………………………………………………………………3
壹、緒論
肝癌…………………………………………5
雙磷酸鹽……………………………………11
紫杉醇………………………………………16
細胞週期……………………………………21
鈣……………………………………………26
貳、實驗目的……………………………………31
參、實驗項目……………………………………32
肆、實驗藥品……………………………………33
伍、實驗方法及進行步驟………………………35
陸、實驗結果……………………………………41
柒、討論…………………………………………52
捌、結論…………………………………………64
玖、參考文獻……………………………………65
拾、圖表…………………………………………81
Aden DP, Fogel A, Plotkin S, Damjanov I and Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282: 615-6, 1979
Amundson SA, Myers TG and Fornace AJ Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17: 3287-99, 1998
Beasley RP, Hwang LY, Lin CC and Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet 2: 1129-33, 1981
Bendhack LM, Sharma RV and Bhalla RC. Altered signal transduction in vascular smooth muscle cells of spontaneously hypertensive rats. Hypertension 19: II142-8, 1992
Benford HL, Frith JC, Auriola S, Monkkonen J and Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Molecular Pharmacology 56: 131-40, 1999
Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J and Knight RD. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine 334: 488-93, 1996
Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J and Knight RD. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Journal of Clinical Oncology 16: 593-602, 1998
Berridge MJ. Calcium signalling and cell proliferation. Bioessays 17: 491-500, 1995
Berridge MJ, Downes CP and Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 59: 411-9, 1989
Berridge MJ and Irvine RF. Inositol phosphates and cell signalling. Nature 341: 197-205, 1989
Bisaz S, Jung A and Fleisch H. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clinical Science & Molecular Medicine 54: 265-72, 1978
Boulenc X, Marti E, Joyeux H, Roques C, Berger Y and Fabre G. Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model. Biochemical Pharmacology 46: 1591-600, 1993
Bounameaux HM, Schifferli J, Montani JP, Jung A and Chatelanat F. Renal failure associated with intravenous diphosphonates. Lancet 1: 471, 1983
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 248-54, 1976
Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, Ventura M, Vall M, Bruguera M, Bru C, Castillo R and Rodes J. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2: 1004-6, 1989
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M and Rodes J. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. Journal of Hepatology 35: 421-30, 2001
Buiting AM, Zhou F, Bakker JA, van Rooijen N and Huang L. Biodistribution of clodronate and liposomes used in the liposome mediated macrophage ''suicide'' approach. Journal of Immunological Methods 192: 55-62, 1996
Cabral F, Wible L, Brenner S and Brinkley BR. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. Journal of Cell Biology 97: 30-9, 1983
Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA and Slingerland JM. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Research 59: 684-8, 1999
Chang C, Hu CP, Tang T, Chou CF, Ting LP and Chou CK. The differentiation properties of human hepatoma cell lines. In Molecular biology of neoplasia. Chan EH, Lin JK, and Huang PC.(ed). Taipei, Academia Sinica, pp262-269, 1985
Chang C, Lin Y, O-Lee TW, Chou CK, Lee TS, Liu TJ, P''eng FK, Chen TY and Hu CP. Induction of plasma protein secretion in a newly established human hepatoma cell line. Molecular & Cellular Biology 3: 1133-7, 1983
Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P''eng FK and Chi CW. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 77: 14-8, 1996
Chao Y, Chan WK, Birkhofer MJ, Hu OY, Wang SS, Huang YS, Liu M, Whang-Peng J, Chi KH, Lui WY and Lee SD. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. British Journal of Cancer 78: 34-9, 1998
Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL and Palmiter RD. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59: 1145-56, 1989
Ciapa B, Pesando D, Wilding M and Whitaker M. Cell-cycle calcium transients driven by cyclic changes in inositol trisphosphate levels. Nature 368: 875-8, 1994
Cittadini A, Bossi D, Dani AM, Calviello G, Wolf F and Terranova T. Lack of effect of the Ca2+ ionophore A23187 on tumour cells. Biochimica et Biophysica Acta 645: 177-82, 1981
Connell-Crowley L, Harper JW and Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Molecular Biology of the Cell 8: 287-301, 1997
Conrad KA and Lee SM. Clodronate kinetics and dynamics. Clinical Pharmacology & Therapeutics 30: 114-20, 1981
Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G and Ford JM. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. Journal of Clinical Oncology 14: 2552-9, 1996
Cory AH, Owen TC, Barltrop JA and Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Communications 3: 207-12, 1991
De la Pompa JL, Timmerman LA, Takimoto H, Yoshida H, Elia AJ, Samper E, Potter J, Wakeham A, Marengere L, Langille BL, Crabtree GR and Mak TW. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 392: 182-6, 1998
Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL
and Bataille R. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. Journal of Bone & Mineral Research 14: 2048-56, 1999
Desai AG, Schaffer B and Park CH. Accumulation of bone-scanning agents in hepatoma. Radiology 149: 292, 1983
Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 26: 34S-38S, 1997
Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M
and Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine 339: 357-63, 1998
Dustin P. Microtubules. Scientific American 243: 66-76, 1980
El-Serag HB. Epidemiology of hepatocellular carcinoma. Clinics in Liver Disease 5: 87-107, 2001
Ettinger DS, Finkelstein DM, Sarma RP and Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 13: 1430-5, 1995
Evans T, Rosenthal ET, Youngblom J, Distel D and Hunt T. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 33: 389-96, 1983
Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA and Reszka AA. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proceedings of the National Academy of Sciences of the United States of America 96: 133-8, 1999
Fleisch H and Bisaz S. Isolation from urine of pyrophosphonate, a calcification inhibitor. American Journal of physiology 203: 671-5, 1962
Fleisch H, Russell RG and Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212: 901-3, 1966
Fleisch H, Russell RG, Bisaz S, Casey P and Muhlbauer RC. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcified Tissue Research 2: Suppl: 10-10a, 1968
Fleisch HA, Russell RG, Bisaz S, Muhlbauer RC and Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. European Journal of Clinical Investigation 1: 12-8, 1970
Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT and Greig WR. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. Journal of Nuclear Medicine 19: 270-5, 1978
Forastiere AA, Neuberg D, Taylor SG 4th, DeConti R and Adams G. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial. Journal of the National Cancer Institute (Monographs) 15: 181-4, 1993
Francis MD, Russell RG and Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165: 1264-6, 1969
Frith JC, Monkkonen J, Blackburn GM, Russell RG and Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5''-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. Journal of Bone & Mineral Research 12: 1358-67, 1997
Fromigue O, Lagneaux L and Body JJ. Bisphosphonates induce breast cancer cell death in vitro. Journal of Bone & Mineral Research 15: 2211-21, 2000
Fulton BP and Whittingham DG. Activation of mammalian oocytes by intracellular injection of calcium. Nature 273: 149-51, 1978
Galmarini CM, Falette N, Tabone E, Levrat C, Britten R, Voorzanger-Rousselot N, Roesch-Gateau O, Vanier-Viornery A, Puisieux A and Dumontet C. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. British Journal of Cancer 85: 902-8, 2001
Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, Gifford A, Sardet C and Weinberg RA. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12: 1173-80, 1996
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W and Brodeur GM. Expression of a multidrug resistance gene in human cancers. Journal of the National Cancer Institute 81: 116-24, 1989
Goodrich DW, Wang NP, Qian YW, Lee EY and Lee WH. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67: 293-302, 1991
Hall M and Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Advances in Cancer Research 68: 67-108, 1996
Health and Vital Statistics. Taiwan Area, R.O.C. pp77-87, 2001
Hoekstra MF. Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family. Current Opinion in Genetics & Development 7: 170-5, 1997
Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. Journal of the National Cancer Institute 83: 1797-805, 1991
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J and Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. New England Journal of Medicine 335: 1785-91, 1996
Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ and Yang CP. Taxol: mechanisms of action and resistance. Journal of the National Cancer Institute (Monographs) 15: 55-61, 1993
Hughes DE, MacDonald BR, Russell RG and Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. Journal of Clinical Investigation 83: 1930-5, 1989
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR and Boyce BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Journal of Bone & Mineral Research 10: 1478-87, 1995
Ince N and Wands JR. The increasing incidence of hepatocellular carcinoma. New England Journal of Medicine 340: 798-9, 1999
Jagdev SP, Coleman RE, Shipman CM, Rostami-H A and Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. British Journal of Cancer 84: 1126-34, 2001
Jamis-Dow CA, Klecker RW, Katki AG and Collins JM. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemotherapy & Pharmacology 36: 107-14, 1995
Johnson PJ. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. Journal of Gastroenterology & Hepatology 14 Suppl: S32-6, 1999
Kamm KE and Stull JT. The function of myosin and myosin light chain kinase phosphorylation in smooth muscle. Annual Review of Pharmacology & Toxicology 25: 593-620, 1985
Kanematsu T, Furuta T, Takenaka K, Matsumata T, Yoshida Y, Nishizaki T, Hasuo K and Sugimachi K. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 10: 98-102, 1989
Kasting GB and Francis MD. Retention of etidronate in human, dog, and rat. Journal of Bone & Mineral Research 7: 513-22, 1992
Kidd JF, Pilkington MF, Schell MJ, Fogarty KE, Skepper JN, Taylor CW and Thorn P. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. Journal of Biological Chemistry 277: 6504-10, 2002
Kirby JC, Bartow JH, Dresser TP and Winebright JW. Accumulation of MDP in hepatic metastases from mucinous adenocarcinoma of the colon. Clinical Nuclear Medicine 7: 25-7, 1982
Knoblich JA, Sauer K, Jones L, Richardson H, Saint R and Lehner CF. Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation. Cell 77: 107-20, 1994
Knowles BB, Howe CC and Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-9, 1980
Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B and Liotta LA. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Research 56: 569-73, 1996
Lai EC, Choi TK, Tong SW, Ong GB and Wong J. Treatment of unresectable hepatocellular carcinoma: results of a randomized controlled trial. World Journal of Surgery 10: 501-9, 1986
Legha SS, Ring S, Papadopoulos N, Raber M and Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer 65: 2478-81, 1990
Li MS, Li PF, He SP, Du GG and Li G. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line. World Journal of Gastroenterology 8: 469-75, 2002a
Li MS, Li PF, Li G and Du GG. Enhancement of proliferation of HeLa cells by the alpha-fetoprotein. Acta Biochimica et Biophysica Sinica 34: 769-74, 2002b
Lin HL, Chang YF, Liu TY, Wu CW and Chi CW. Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. Anticancer Research 18: 3443-9, 1998
Lin HL, Liu TY, Chau GY, Lui WY and Chi CW. Comparison of 2-methoxyestradiol- induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 89: 983-94, 2000
Lin JH, Duggan DE, Chen IW and Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metabolism & Disposition 19: 926-32, 1991
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM and Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Medicine 3: 231-4, 1997
Long BH and Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Research 54: 4355-61, 1994
Lowik CW, van der Pluijm G, van der Wee-Pals LJ, van Treslong-De Groot HB and Bijvoet OL. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. Journal of Bone & Mineral Research 3: 185-92, 1988
Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G and Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of Bone & Mineral Research 13: 581-9, 1998
Lui WY, Chang YF, Li LL, Ho LK, Su TL, Chen JY, Liu TY, P''Eng FK and Chi CW. Differential paclitaxel-induced cytotoxicity in rodent and human hepatoma cell lines. Anticancer Research 18: 3339-45, 1998
Lukas J, Herzinger T, Hansen K, Moroni MC, Resnitzky D, Helin K, Reed SI and Bartek J. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes & Development 11: 1479-92, 1997
Magnetto S, Boissier S, Delmas PD and Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. International Journal of Cancer 83: 263-9, 1999
Mandell GA and Heyman S. Accumulation of MDP in primary childhood hepatic malignancies and their metastases. Clinical Nuclear Medicine 8: 594-6, 1983
Manfredi JJ and Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacology & Therapeutics 25: 83-125, 1984
Marshall CJ. Protein prenylation: a mediator of protein-protein interactions. Science 259: 1865-6, 1993
Martins LM, Mesner PW, Kottke TJ, Basi GS, Sinha S, Tung JS, Svingen PA, Madden BJ, Takahashi A, McCormick DJ, Earnshaw WC and Kaufmann SH. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood 90: 4283-96, 1997
Matsubara K and Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Molecular Biology & Medicine 7: 243-60, 1990
McConkey DJ, Nicotera P, Hartzell P, Bellomo G, Wyllie AH and Orrenius S. Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca2+ concentration. Archives of Biochemistry & Biophysics 269: 365-70, 1989
McGuire WP. Paclitaxel in the treatment of ovarian cancer. In: Proceedings of the 30th Annual Meeting of the American Society of Clinical Oncology, Dallas, May 14-17, 1994. American Society of Clinical Oncology Educational Book. Chicago: American Society of Clinical Oncology, 204-13, 1994
McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK and Donehower RC. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Annals of Internal Medicine 111: 273-9, 1989
McPherson PS and Campbell KP. The ryanodine receptor/Ca2+ release channel. Journal of Biological Chemistry 268: 13765-8, 1993
Monkkonen H, Moilanen P, Monkkonen J, Frith JC, Rogers MJ and Auriola S. Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography-electrospray ionisation mass spectrometry. Journal of Chromatography. B, Biomedical Sciences & Applications 738: 395-403, 2000
Monsarrat B, Alvinerie P, Wright M, Dubois J, Gueritte-Voegelein F, Guenard D, Donehower RC and Rowinsky EK. Hepatic metabolism and biliary excretion of Taxol in rats and humans. Journal of the National Cancer Institute (Monographs) 15: 39-46, 1993
Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annual Review of Cell & Developmental Biology 13: 261-91, 1997
Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H and Raber MN. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. Journal of the National Cancer Institute 85: 384-8, 1993
Nicholls DG. The regulation of extramitochondrial free calcium ion concentration by rat liver mitochondria. Biochemical Journal 176: 463-74, 1978
Ohnishi K, Yoshioka H, Ito S and Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 27: 67-72, 1998
Okadas. Chemotherapy in hepatocellular carcinoma. Hepatogastroenterology 45:1259, 1998
Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, Hayashi H, Asano T and Ryu M. Evaluation of liver tumors using fluorine-18- fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. Journal of Nuclear Medicine 33: 333-9, 1992
Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 15: 948-63, 1992
Oliner JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-3, 1992
O''Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D and Kanis JA. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. British Journal of Cancer 67: 560-3, 1993
Osanai T and Dunn MJ. Phospholipase C responses in cells from spontaneously hypertensive rats. Hypertension 19: 446-55, 1992
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-5, 1995
Pardee AB. A restriction point for control of normal animal cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 71: 1286-90, 1974
Pardee AB. G1 events and regulation of cell proliferation. Science 246: 603-8, 1989
Pignata S, Daniele B, Gallo C, De Vivo R, Monfardini S and Perrone F. Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit?. European Journal of Cancer 34: 25-32, 1998
Poenie M, Alderton J, Tsien RY and Steinhardt RA. Changes of free calcium levels with stages of the cell division cycle. Nature 315: 147-9, 1985
Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes & Development 8: 9-22, 1994
Prives C and Hall PA. The p53 pathway. Journal of Pathology 187: 112-26, 1999
Reszka AA, Halasy-Nagy JM, Masarachia PJ and Rodan GA. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. Journal of Biological Chemistry 274: 34967-73, 1999
Roberts JR, Allison DC, Donehower RC and Rowinsky EK. Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Research 50: 710-6, 1990
Rodan GA and Fleisch HA. Bisphosphonates: mechanisms of action. Journal of Clinical Investigation 97: 2692-6, 1996
Rogers MJ, Brown RJ, Hodkin V, Blackburn GM, Russell RG and Watts DJ. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochemical & Biophysical Research Communications 224: 863-9, 1996
Rogers MJ, Ji X, Russell RG, Blackburn GM, Williamson MP, Bayless AV, Ebetino FH and Watts DJ. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochemical Journal 303: 303-11, 1994
Rogers MJ, Russell RG, Blackburn GM, Williamson MP and Watts DJ. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochemical & Biophysical Research Communications 189: 414-23, 1992
Rogers MJ, Watts DJ and Russell RG. Overview of bisphosphonates. Cancer 80: 1652-60, 1997
Rowinsky EK, Chaudhry V, Cornblath DR and Donehower RC. Neurotoxicity of Taxol. Journal of the National Cancer Institute (Monographs) 15: 107-15, 1993a
Rowinsky EK and Donehower RC. The clinical pharmacology of paclitaxel (Taxol). Seminars in Oncology 20: 16-25, 1993
Rowinsky EK and Donehower RC. Paclitaxel (taxol). New England Journal of Medicine 332: 1004-14, 1995
Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG and Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Seminars in Oncology 20: 1-15, 1993b
Roy SN and Horwitz SB. A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Research 45: 3856-63, 1985
Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E and Rodan GA. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. Journal of Clinical Investigation 88: 2095-105, 1991
Schiff PB, Fant J and Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-7, 1979
Selander KS, Monkkonen J, Karhukorpi EK, Harkonen P, Hannuniemi R and Vaananen HK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Molecular Pharmacology 50: 1127-38, 1996
Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. British Journal of Cancer
82: 1459-68, 2000
Shafritz DA and Kew MC. Identification of integrated hepatitis B virus DNA sequences in human hepatocellular carcinomas. Hepatology 1: 1-8, 1981
Sherr CJ. Cancer cell cycles. Science 274: 1672-7, 1996
Shikata T. Hepatocellular carcinoma. New York, John Wiley & Sons. pp53, 1976
Shipman CM, Croucher PI, Russell RG, Helfrich MH and Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Research 58: 5294-7, 1998
Speicher LA, Barone L and Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Research 52: 4433-40, 1992
Stearns ME and Wang M. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Research 52: 3776-81, 1992
Stillman B. Cell cycle control of DNA replication. Science 274: 1659-64, 1996
Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, Tagliaferri P and Venuta S. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14: 841-4, 2000
Tishler RB, Geard CR, Hall EJ and Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Research 52: 3495-7, 1992
Torres K and Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Research 58: 3620-6, 1998
Vetter D, Wenger JJ, Bergier JM, Doffoel M and Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology 13: 427-33, 1991
Virtanen SS, Vaananen HK, Harkonen PL and Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Research 62: 2708-14, 2002
Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Journal of the American Chemical Society 93: 2325-7, 1971
Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J and Woodcock D. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. Journal of the National Cancer Institute 85: 1685-90, 1993
Wyllie AH. Cell death: a new classification separating apoptosis from necrosis, in Cell Death in Biology and Pathology (Bowen ID and Lockshin RA, eds.) Chapman and Hall, London, pp9-34, 1981
Yakatan GJ, Poynor WJ, Talbert RL, Floyd BF, Slough CL, Ampulski RS and Benedict JJ. Clodronate kinetics and bioavailability. Clinical Pharmacology & Therapeutics 31: 402-10, 1982
Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ and Henderson BE. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Research 49: 2506-9, 1989
Zhang FL and Casey PJ. Protein prenylation: molecular mechanisms and functional
consequences. Annual Review of Biochemistry 65: 241-69, 1996
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊
 
系統版面圖檔 系統版面圖檔